Observational study of ivosidenib use in France for AML
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at patients with a specific type of AML (IDH1 R132 mutation) who received the drug ivosidenib through a compassionate use program in France. It aims to understand how well the drug works and how it's used in real-world practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) with a specific gene change called IDH1 R132 mutation.
- You were treated with ivosidenib through a French compassionate use program between January 1, 2017 and August 1, 2023.
- You received ivosidenib either alone or combined with other AML treatments like azacytidine or venetoclax.
- You were not part of a clinical trial for an IDH inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
This study looks at how leukemia cells become resistant to two common drug combinations: azacitidine plus venetoclax or azacitidine plus ivosidenib. It is for people with newly diagnosed AML who are about to start one of these treatments.
This trial tests a combination of three drugs (ivosidenib, venetoclax, and azacitidine) for adults who have acute myeloid leukemia with a specific IDH1 gene change and have not been treated for AML before. The goal is to find a better first treatment option.
This trial studies ivosidenib together with azacitidine in people newly diagnosed with AML that has an IDH1 R132 gene mutation. It’s meant for patients who are not able to safely receive the strongest (intensive) chemotherapy, with the goal of improving control of the leukemia.
This study tests whether adding a targeted pill (ivosidenib) to another maintenance drug (oral azacitidine) can help keep your leukemia in remission longer. It is for older adults with a specific gene change (IDH1) who have finished intensive chemotherapy.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.